small

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

1 month ago

Addex Convenes Annual General Meeting 2025

June 03, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and…

1 month ago